Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
CONCLUSIONS: BV was safely administered to patients with relapsed/refractory cHL and severe liver function impairment with marked jaundice due to liver involvement, offering significant clinical improvement and reversal of liver abnormalities. BV may serve as a bridge to further salvage combination chemotherapy or a transplant procedure.
PMID: 31983123 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Anemia | Cancer & Oncology | Chemotherapy | Jaundice | Laboratory Medicine | Liver | Liver Transplant | Lymphoma | Pancytopenia | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants | Urology & Nephrology